Drug Overview

Loncastuximab tesirine-lpyl is a targeted anticancer agent designed as an antibody-drug conjugate (ADC). It represents a novel class of immunotherapy for specific B-cell malignancies.

Generic Name: Loncastuximab tesirine-lpyl
US Brand Name: Zynlonta®
Drug Class: Antibody-Drug Conjugate (ADC), CD19-directed cytotoxin
Route of Administration: Intravenous (IV) Infusion
FDA Approval Status: Approved for specific oncological indications.

Mechanism of Action

Loncastuximab tesirine-lpyl is a CD19-directed antibody-drug conjugate that delivers a cytotoxic payload directly to B-cells.

Molecular Target: The antibody component binds specifically to the CD19 antigen, a cell surface protein expressed on B-cells and many B-cell malignancies.
Cellular Impact: Upon binding to CD19, the ADC is internalized into the target cell. Within the cell, the linker is cleaved, releasing the cytotoxic warhead, SG3199 (a pyrrolobenzodiazepine dimer).
Result: The released payload binds to the minor groove of DNA, forming highly potent interstrand cross-links. This cross-linking irreparably damages the DNA, blocking cell division and ultimately triggering apoptotic cell death in the CD19-expressing tumor cell.

FDA-Approved Clinical Indications

Loncastuximab tesirine-lpyl is FDA-approved for a specific hematologic malignancy.

Oncological Indications (Marketed as Zynlonta®):

Relapsed or Refractory Large B-cell Lymphoma: Treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), not otherwise specified, DLBCL arising from low-grade lymphoma and high-grade B-cell lymphoma.

Non-Oncological Indications:

There are currently no FDA-approved non-oncological uses for loncastuximab tesirine-lpyl.

Dosage and Administration Protocols

Loncastuximab tesirine-lpyl is administered as an intravenous infusion. Dosing is weight-based and follows a specific schedule with required premedication.

Standard Oncology Dosage:

Cycle 1 & 2: 0.15 mg/kg administered by IV infusion over 30 minutes every 3 weeks.
Subsequent Cycles (3+): 0.075 mg/kg administered by IV infusion over 30 minutes every 3 weeks.
Premedication: Administer corticosteroids (e.g., dexamethasone) starting the day before infusion, on the day of, and the day after to reduce the risk and severity of fluid retention/edema.

Dose Modification Guidelines:

Dose delays, reductions, or discontinuation are required for specific toxicities.

Toxicity Grade	Recommended Action
Grade 2 (Edema or Effusion)	Interrupt the dose until ≤ Grade 1, then consider dose reduction.
Grade ≥ 3 (Edema or Effusion)	Permanently discontinue.
Grade 3 (Neutropenia)	Interrupt until ANC ≥ 1,000/mm³, then resume at the same dose.
Grade 4 (Neutropenia)	Interrupt until ANC ≥ 1,000/mm³, then resume at reduced dose:• 0.075 mg/kg → 0.05 mg/kg• 0.15 mg/kg → 0.075 mg/kg
Other Grade 3-4 (Non-Hematologic)	Interrupt until ≤ Grade 1, then resume at reduced dose or discontinue based on severity/recurrence.

Clinical Efficacy and Research Outcomes

Clinical data from the pivotal LOTIS-2 trial and follow-up studies establish the efficacy of loncastuximab tesirine in heavily pre-treated large B-cell lymphoma.

Pivotal Trial Results: In the phase 2 LOTIS-2 trial of patients with r/r DLBCL after ≥2 prior therapies, loncastuximab tesirine demonstrated an Overall Response Rate (ORR) of 48.3%, with a Complete Response (CR) rate of 24.1%. The median duration of response (DOR) for all responders was 10.3 months.
Real-World Effectiveness: Post-marketing data and real-world evidence studies (2022-2024) corroborate these efficacy signals in broader, heterogeneous populations outside clinical trials, showing manageable toxicity and meaningful clinical benefit where other options are limited.
Combination Therapy Research: Ongoing clinical trials (2020-2025) are actively investigating loncastuximab tesirine in combination with other agents. Key areas include combinations with Bruton’s tyrosine kinase (BTK) inhibitors in mantle cell lymphoma and with immunomodulatory drugs or chemotherapy in earlier lines of therapy for DLBCL, aiming to improve depth and duration of response.

Safety Profile and Side Effects

Black Box Warning:

Edema and Effusion: Serious and fatal edema and effusion can occur. Monitor for new or worsening symptoms.

Common Side Effects (>20%):

Hematologic: Thrombocytopenia, neutropenia, anemia.
General: Fatigue, edema (peripheral, generalized), rash.
Biochemical: Increased gamma-glutamyltransferase (GGT), hyperglycemia.
Other: Nausea, musculoskeletal pain, dyspnea.

Serious Adverse Events

Edema and Effusions: Includes peripheral edema, pleural effusion, pericardial effusion, and ascites. Managed with premedication steroids, dose delays/interruptions, and diuretics. Severe cases require permanent discontinuation.
Myelosuppression: Severe neutropenia, thrombocytopenia, and anemia. Monitor blood counts. Manage with dose delays, growth factor support, or transfusions.
Infections: Serious infections, including pneumonia and sepsis, can occur due to neutropenia. Monitor for signs of infection.
Skin Reactions: Rash, including severe reactions. May require topical/systemic steroids, antihistamines, or dose modification.

Connection to Stem Cell & Regenerative Medicine

As a targeted cytotoxic therapy, loncastuximab tesirine-lpyl’s primary role is in direct tumour cell killing, but it interfaces with cellular therapy paradigms.

Bridge to Cellular Therapies: For patients with relapsed/refractory large B-cell lymphoma, achieving disease reduction with loncastuximab tesirine can serve as a potential “bridge therapy” to definitive consolidative treatments like chimeric antigen receptor (CAR) T-cell therapy or autologous stem cell transplantation (ASCT) by reducing tumour burden.
Research in Combination with CAR-T: Early-phase investigations are exploring the sequential or combination use of CD19-targeting ADCs with CD19-directed CAR T-cells. The hypothesis is that the ADC may help modulate the tumour microenvironment or target heterogeneous CD19 expression, potentially improving outcomes of subsequent cellular immunotherapy.

Patient Management and Practical Recommendations

Pre-Treatment

Laboratory Tests: Obtain complete blood count (CBC) with differential, comprehensive metabolic panel (including liver enzymes and glucose), and serum albumin.
Cardiopulmonary Assessment: Evaluate baseline fluid status and assess for signs of pre-existing effusions or edema. Consider baseline imaging (e.g., chest X-ray) if symptoms suggest.
Premedication Plan: Ensure a corticosteroid premedication schedule is clearly prescribed and understood by the patient (e.g., dexamethasone 4 mg twice daily for 3 days starting the day before infusion).

During Treatment

Monitoring: Monitor for signs/symptoms of edema or effusion (weight gain, new or worsening cough, dyspnea, peripheral swelling) before each infusion. Monitor CBC before each dose.
Infusion: Administer via IV infusion over 30 minutes. Do not administer as an IV push or bolus.
Hydration: Maintain appropriate hydration, but avoid overhydration, which may exacerbate edema risk.

Do’s and Don’ts

DO: Take corticosteroid premedication exactly as prescribed.
DO: Weigh yourself regularly and report sudden weight gain, swelling, or new shortness of breath immediately.
DO: Report fever, signs of infection, or unusual bruising/bleeding.
DON’T: Miss scheduled blood tests before each treatment cycle.
DON’T: Delay reporting new respiratory or cardiac symptoms.

Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status, specific disease characteristics, and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding any medical condition or treatment decision.